Osaka, Japan, April 5, 2024 - Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino) announced that it has decided changes of the Board of Directors, Audit & Supervisory Board Members and Corporate Officers at the meeting of the Board of Directors held today.
　The appointments for candidates of the Board of Directors and Audit & Supervisory Board Members will be resolved at the 76th Annual Shareholders Meeting scheduled for June 2024. The changes and appointments of the Board of Directors and Corporate Officers will be officially decided at the meeting of the Board of Directors to be held on the same day after the Annual Shareholders Meeting.

１．Changes of the position of the Board of Directors (scheduled for June 2024):
　　Except for the following Board of Director, incumbent of the Board of Directors will be re-appointed.
-Resigning Board of Director:
Kiyoaki Idemitsu　Executive Officer / Chief Officer, Clinical Development

２．Changes of Audit & Supervisory Board Members (scheduled for June 2024):
　　Except for the following candidates of Audit & Supervisory Board Members, the incumbent Members will be in term.

- New candidate of Audit & Supervisory Board Member
　Kiyoaki Idemitsu

- Resigning Audit & Supervisory Board Membe
　Katsuyoshi Nishimura
　*: After resigning, he will be appointed as a part-time adviser.
　Yasuo Hishiyama (outside) will be re-appointed.

３．Changes of Corporate Officers (scheduled for June 2024):
　　Except for the following candidates of Corporate Officers, incumbent Corporate Officers will be re-appointed.
- New candidate of Corporate Officers

Hirokazu Kitada

Senior Director, Osaka Branch Sales Division

Yasushi Hirota

Executive Director, Corporate Regulatory Compliance, Safety and Quality Assurance

Seishi Katsumata

Executive Director, Discovery & Research, Research Project Management Division

Kunihiko Ito

President, Ono Pharma USA，Inc.

< Reference >
The followings are the appointments of the Board of Directors, Audit & Supervisory Board Members as well as Corporate Officers (scheduled for June 2024).
*: Candidates of the Board of Directors, and Audit & Supervisory Board Members for subject to approval at the 76th Annual Shareholders Meeting

The Board of Directors:

Audit & Supervisory Board Members:

- Gyo Sagara*

Representative Director, Chairman of the Board and Chief Executive Officer

- Toichi Takino*

Representative Director, President and Chief Operating Officer

- Toshihiro Tsujinaka*

Representative Director, Executive Vice President / Executive Director, Corporate Strategy & Planning, Business Design, Sustainability Promotion

- Masao Nomura*

Outside Director

- Akiko Okuno*

Outside Director

- Shusaku Nagae*

Outside Director

- Hironobu Tanisaka

Audit & Supervisory Board Member (full-time)

- Kiyoaki Idemitsu*

Audit & Supervisory Board Member (full-time)

- Yasuo Hishiyama*

- Outside Audit & Supervisory Board Membe

- Akiko Tanabe

Outside Audit & Supervisory Board Member

Corporate Officers:

- Akira Takada

Corporate Executive Officer / Executive Director, CMC & Production

- Satoshi Takahagi

Corporate Executive Officer / Executive Director, Sales and Marketing, Primary Care Business Division

- Hiromu Habashita

Corporate Officer / Deputy Executive Director, Discovery & Research

- Shinji Takai

Corporate Officer / Head of Medical Affairs

- Masaki Ito

Corporate Officer / Division Director, Corporate Strategy & Planning, Business Management Division, Business Management Department, Finance & Accounting／ President, Ono Digital health Investment, GK.

- Tatsuya Okamaoto

Corporate Officer / Executive Director, Clinical Development, Oncology Clinical Development Division, Global Project Management

- Masayuki Tanigawa

Corporate Officer, Executive Director, Corporate Development & Strategy

- Takehiro Yamada

Corporate Officer / Senior Director, Risk & Compliance Management Department

- Hirokazu Kitada

Corporate Officer / Senior Director, Osaka Branch Sales Division

- Yasushi Hirota

Corporate Officer / Executive Director, Corporate Regulatory Compliance, Safety and Quality Assurance

- Seishi Katsumata

Corporate Officer / Executive Director, Discovery & Research, Research Project Management Division

- Kunihiko Ito

Corporate Officer / President, Ono Pharma USA, Inc.

Attachments

  • Original Link
  • Permalink

Disclaimer

ONO Pharmaceutical Co. Ltd. published this content on 05 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 April 2024 04:06:03 UTC.